These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 37729551)

  • 21. Prostate biopsy in the era of MRI-targeting: towards a judicious use of additional systematic biopsy.
    Deniffel D; Perlis N; Ghai S; Girgis S; Healy GM; Fleshner N; Hamilton R; Kulkarni G; Toi A; van der Kwast T; Zlotta A; Finelli A; Haider MA
    Eur Radiol; 2022 Nov; 32(11):7544-7554. PubMed ID: 35507051
    [TBL] [Abstract][Full Text] [Related]  

  • 22. PI-RADS v2 and periprostatic fat measured on multiparametric magnetic resonance imaging can predict upgrading in radical prostatectomy pathology amongst patients with biopsy Gleason score 3 + 3 prostate cancer.
    Zhai L; Fan Y; Sun S; Wang H; Meng Y; Hu S; Wang X; Yu W; Jin J
    Scand J Urol; 2018; 52(5-6):333-339. PubMed ID: 30895901
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Gleason Grade Group Concordance between Systematic Template Combining Magnetic Resonance Imaging Fusion Targeted Biopsy and Radical Prostatectomy Specimens: A Comparison of Transperineal and Transrectal Approaches.
    Wu S; Feldman AS; Kim MM; Lin SX; Cornejo KM; Harisinghani MG; Dahl DM; Wu CL
    Urology; 2023 May; 175():151-156. PubMed ID: 36828261
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Suboptimal Prediction of Clinically Significant Prostate Cancer in Radical Prostatectomy Specimens by mpMRI-Targeted Biopsy.
    Karsiyakali N; Ozgen MB; Ozveren B; Akbal C; Dincer A; Durak H; Turkeri L
    Urology; 2021 Feb; 148():217-223. PubMed ID: 32871139
    [TBL] [Abstract][Full Text] [Related]  

  • 25. PI-RADS Version 2 Category on 3 Tesla Multiparametric Prostate Magnetic Resonance Imaging Predicts Oncologic Outcomes in Gleason 3 + 4 Prostate Cancer on Biopsy.
    Faiena I; Salmasi A; Mendhiratta N; Markovic D; Ahuja P; Hsu W; Elashoff DA; Raman SS; Reiter RE
    J Urol; 2019 Jan; 201(1):91-97. PubMed ID: 30577397
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Combination MRI-targeted and systematic prostate biopsy may overestimate gleason grade on final surgical pathology and impact risk stratification.
    Yu A; Yamany T; Mojtahed A; Hanna N; Nicaise E; Harisinghani M; Wu CL; Dahl DM; Wszolek M; Blute ML; Feldman AS
    Urol Oncol; 2022 Feb; 40(2):59.e1-59.e5. PubMed ID: 34544650
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Tailoring biopsy strategy in the MRI-fusion prostate biopsy era: systematic, targeted or neither?
    Jäderling F; Bergman M; Engel JC; Mortezavi A; Picker W; Haug ES; Eklund M; Nordström T
    BMC Urol; 2024 Aug; 24(1):168. PubMed ID: 39112967
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Analysis of PI-RADS 4 cases: Management recommendations for negatively biopsied patients.
    Ullrich T; Arsov C; Quentin M; Laqua N; Klingebiel M; Martin O; Hiester A; Blondin D; Rabenalt R; Albers P; Antoch G; Schimmöller L
    Eur J Radiol; 2019 Apr; 113():1-6. PubMed ID: 30927932
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Diagnostic Accuracy and Interobserver Agreement of PI-RADS Version 2 and Version 2.1 for the Detection of Transition Zone Prostate Cancers.
    Wei CG; Zhang YY; Pan P; Chen T; Yu HC; Dai GC; Tu J; Yang S; Zhao WL; Shen JK
    AJR Am J Roentgenol; 2021 May; 216(5):1247-1256. PubMed ID: 32755220
    [No Abstract]   [Full Text] [Related]  

  • 30. Prospective Evaluation of PI-RADS Version 2.1 for Prostate Cancer Detection and Investigation of Multiparametric MRI-derived Markers.
    Yilmaz EC; Shih JH; Belue MJ; Harmon SA; Phelps TE; Garcia C; Hazen LA; Toubaji A; Merino MJ; Gurram S; Choyke PL; Wood BJ; Pinto PA; Turkbey B
    Radiology; 2023 May; 307(4):e221309. PubMed ID: 37129493
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The Role of PSA Density among PI-RADS v2.1 Categories to Avoid an Unnecessary Transition Zone Biopsy in Patients with PSA 4-20 ng/mL.
    Wang ZB; Wei CG; Zhang YY; Pan P; Dai GC; Tu J; Shen JK
    Biomed Res Int; 2021; 2021():3995789. PubMed ID: 34671673
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Transcriptome Wide Analysis of Magnetic Resonance Imaging-targeted Biopsy and Matching Surgical Specimens from High-risk Prostate Cancer Patients Treated with Radical Prostatectomy: The Target Must Be Hit.
    Radtke JP; Takhar M; Bonekamp D; Kesch C; Erho N; du Plessis M; Buerki C; Ong K; Davicioni E; Hohenfellner M; Hadaschik BA
    Eur Urol Focus; 2018 Jul; 4(4):540-546. PubMed ID: 28753844
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The Impact of Visible Tumor (PI-RADS ≥ 3) on Upgrading and Adverse Pathology at Radical Prostatectomy in Low Risk Prostate Cancer Patients: A Biopsy Core Based Analysis.
    Özkan A; Köseoğlu E; Kılıç M; Baydar DE; Sağlıcan Y; Balbay MD; Canda AE; Kordan Y; Kiremit MC; Çil B; Tuğcu V; Bakır B; Esen T
    Clin Genitourin Cancer; 2022 Feb; 20(1):e61-e67. PubMed ID: 34750082
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Prostate cancer upgrading with serial prostate magnetic resonance imaging and repeat biopsy in men on active surveillance: are confirmatory biopsies still necessary?
    Osses DF; Drost FH; Verbeek JFM; Luiting HB; van Leenders GJLH; Bangma CH; Krestin GP; Roobol MJ; Schoots IG
    BJU Int; 2020 Jul; 126(1):124-132. PubMed ID: 32232921
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Predictors of prostate cancer detection in MRI PI-RADS 3 lesions - Reality of a tertiary center.
    Araújo D; Gromicho A; Dias J; Bastos S; Maciel RM; Sabença A; Xambre L
    Arch Ital Urol Androl; 2023 Dec; 95(4):11830. PubMed ID: 38117217
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Diagnostic accuracy of multiparametric MRI- and microultrasound-targeted biopsy in biopsy-naïve patients with a PI-RADS 5 lesion: a single-institutional study.
    Avolio PP; Fasulo V; Sanchez-Salas R; Maffei D; Frego N; Lazzeri M; Paciotti M; Saita A; Hurle R; Guazzoni G; Casale P; Buffi NM; Lughezzani G
    World J Urol; 2023 Sep; 41(9):2335-2342. PubMed ID: 37418017
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A novel nomogram to identify candidates for active surveillance amongst patients with International Society of Urological Pathology (ISUP) Grade Group (GG) 1 or ISUP GG2 prostate cancer, according to multiparametric magnetic resonance imaging findings.
    Luzzago S; de Cobelli O; Cozzi G; Peveri G; Bagnardi V; Catellani M; Di Trapani E; Mistretta FA; Pricolo P; Conti A; Alessi S; Marvaso G; Ferro M; Matei DV; Renne G; Jereczek-Fossa BA; Petralia G; Musi G
    BJU Int; 2020 Jul; 126(1):104-113. PubMed ID: 32150328
    [TBL] [Abstract][Full Text] [Related]  

  • 38. How to make clinical decisions to avoid unnecessary prostate screening in biopsy-naïve men with PI-RADs v2 score ≤ 3?
    Zhang Y; Zeng N; Zhang F; Huang Y; Tian Y
    Int J Clin Oncol; 2020 Jan; 25(1):175-186. PubMed ID: 31473884
    [TBL] [Abstract][Full Text] [Related]  

  • 39. PI-RADS Upgrading Rules: Impact on Prostate Cancer Detection and Biopsy Avoidance of MRI-Directed Diagnostic Pathways.
    de Oliveira Correia ET; Purysko AS; Paranhos BM; Shoag JE; Padhani AR; Bittencourt LK
    AJR Am J Roentgenol; 2024 May; 222(5):e2330611. PubMed ID: 38353450
    [No Abstract]   [Full Text] [Related]  

  • 40. In-Bore Versus Fusion MRI-Targeted Biopsy of PI-RADS Category 4 and 5 Lesions: A Retrospective Comparative Analysis Using Propensity Score Weighting.
    Prince M; Foster BR; Kaempf A; Liu JJ; Amling CL; Isharwal S; Chen Y; Coakley FV
    AJR Am J Roentgenol; 2021 Nov; 217(5):1123-1130. PubMed ID: 33646819
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.